TORONTO, Aug. 22, 2018 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical
company specializing in central nervous system ("CNS") and
cardiovascular markets, announces that it has granted, effective
today, an aggregate of 538,506 stock options (each an "Option") to
certain directors, officers, employees and consultants of the
Company in accordance with the Company's amended and restated stock
option plan. Each Option is exercisable into one common share (a
"Share") of the Company at a price of $8.34 per Share for a
period of seven years from the date of grant, being today. The
Options will vest in quarterly instalments over a four year period,
beginning on the date that is twelve months from the date
hereof.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company
focused on the acquisition and commercialization of late stage
development, commercial stage promoted and established branded
pharmaceutical products in the North American markets. HLS's focus
is on products targeting the central nervous system and
cardiovascular therapeutic areas. HLS's management team is composed
of seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE HLS Therapeutics Inc.